Ann: Invex Granted European Orphan Drug Designation for TBI, page-16

After todays TBI secondary indication announcement, we are now chasing a $4B TAM - triples our upside, diversifies our downside

And with @jellyroll 's research into the IXC patent for Glaucoma and our board members OPT CEO Megan Baldwin, I think I have just clocked what IXC management are doing:

- Run a Phase III for IIH with a strong Mechanism of Action that translates across many indications with raised ICP.
- Acquire a portfolio of multiple secondary indications IP to magnify the upside of M&A Exit value
- Not invest a further dollar regarding R&D for these secondary indications, but own the exclusive Orphan rights to sell GLP-1RAs for them for 10 years.
- Sell post Phase III to a major pharma company for a few B's (hundreds of millions more than what they could if it was only IIH).

I am a big fan of this approach; best maximisation of shareholder value, lowest cost (No need for CR) and shortest time to exit.

Congratulations to the team.